CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Anakinra and Ruxolitinib (overcome stage 3)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug47 Anakinra alone (stages 2b/3) Wiki 1.00
drug775 Standard of care Wiki 0.35

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D007249 Inflammation NIH 0.45

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Interleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation: Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and Ruxolitinib

During SARS-Cov2 infection with serious respiratory implication and high systemic inflammation level, intravenous ANAKINRA alone or associated with RUXOLITINIB for severe cases might reduce inappropriate systemic inflammatory response, improve breathing and decrease occurrence or duration of ARDS and associated mortality.

NCT04366232 Covid-19 Drug: Anakinra alone (stages 2b/3) Drug: Anakinra and Ruxolitinib (overcome stage 3) Other: Standard of care
MeSH:Inflammation

Primary Outcomes

Description: At least 3 parameters are met including CRP and/or Ferritin among: CRP: decrease > 50% Ferritinemia: decrease > 1/3 Serum creatinine: decrease > 1/3 AST/ALT: decrease > 50% Eosinophils > 50 /mm3 Lymphocytes > 1000 /mm3

Measure: Biological criteria

Time: 7 days from enrolment

Secondary Outcomes

Description: Time to become afebrile for a minimum period of 48 hours, without antipyretics

Measure: Time to become afebrile

Time: 28 days from enrolment

Description: Number of days without mechanical ventilation

Measure: Duration of oxygen therapy (days)

Time: 28 days from enrolment

Description: Evolution from clinical stage 2b/3 to overcome stage 3 Admission in Intensive Care Unit

Measure: Number of days without mechanical ventilation

Time: 28 days from enrolment

Other Outcomes

Measure: Number of bacterial and/or fungal sepsis

Time: 28 days from enrolment

Measure: Incidence of serious and non-serious adverse events

Time: 28 days from enrolment

No related HPO nodes (Using clinical trials)